This project will provide relevant clinical information for primary care practitioners
treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo-
controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and
carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated
alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a
1-week posttreatment followup.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)